Savara, Inc. (SVRA)
5.35
+0.09
(+1.71%)
USD |
NASDAQ |
Aug 31, 14:00
Savara Free Cash Flow : -110.66M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -110.66M |
| March 31, 2026 | -106.97M |
| December 31, 2025 | -101.06M |
| September 30, 2025 | -99.27M |
| June 30, 2025 | -99.41M |
| March 31, 2025 | -95.65M |
| December 31, 2024 | -89.11M |
| September 30, 2024 | -81.47M |
| June 30, 2024 | -72.00M |
| March 31, 2024 | -59.98M |
| December 31, 2023 | -51.36M |
| September 30, 2023 | -44.38M |
| June 30, 2023 | -39.34M |
| March 31, 2023 | -38.17M |
| December 31, 2022 | -34.56M |
| September 30, 2022 | -35.32M |
| June 30, 2022 | -36.09M |
| March 31, 2022 | -38.97M |
| December 31, 2021 | -40.14M |
| September 30, 2021 | -43.04M |
| June 30, 2021 | -40.82M |
| March 31, 2021 | -36.40M |
| December 31, 2020 | -43.13M |
| September 30, 2020 | -40.78M |
| June 30, 2020 | -45.48M |
| Date | Value |
|---|---|
| March 31, 2020 | -50.65M |
| December 31, 2019 | -45.27M |
| September 30, 2019 | -45.87M |
| June 30, 2019 | -43.23M |
| March 31, 2019 | -40.68M |
| December 31, 2018 | -39.42M |
| September 30, 2018 | -38.77M |
| June 30, 2018 | -38.24M |
| March 31, 2018 | -35.52M |
| December 31, 2017 | -28.73M |
| September 30, 2017 | -21.02M |
| June 30, 2017 | -15.63M |
| March 31, 2017 | 0.052M |
| December 31, 2016 | -8.378M |
| September 30, 2016 | -15.05M |
| June 30, 2016 | -20.46M |
| March 31, 2016 | -37.03M |
| December 31, 2015 | -33.11M |
| September 30, 2015 | -30.28M |
| June 30, 2015 | -27.39M |
| March 31, 2015 | -25.93M |
| December 31, 2014 | -24.79M |
| September 30, 2014 | -23.63M |
| June 30, 2014 | -22.03M |
| March 31, 2014 | -19.62M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Gilead Sciences, Inc. | 12.94B |
| Insmed, Inc. | -837.67M |
| United Therapeutics Corp. | 1.084B |
| Vertex Pharmaceuticals, Inc. | 3.796B |
| SELLAS Life Sciences Group, Inc. | -28.42M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -29.75M |
| Cash from Investing (Quarterly) | 32.60M |
| Cash from Financing (Quarterly) | 0.189M |
| Free Cash Flow Per Share (Quarterly) | -0.1182 |
| Free Cash Flow to Equity (Quarterly) | -30.26M |
| Free Cash Flow to Firm (Quarterly) | -29.97M |
| Free Cash Flow Yield | -8.59% |